{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:06:05Z","timestamp":1778267165956,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.xphs.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T11:08:48Z","timestamp":1560337728000},"page":"3396-3407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Hybrid Nanostructured Films for Topical Administration of Simvastatin as Coadjuvant Treatment of Melanoma"],"prefix":"10.1016","volume":"108","author":[{"given":"Antonella","family":"Barone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9lia","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Mare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Vitorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2019.06.002_bib1","series-title":"Skin Cancers-Risk Factors, Prevention and Therapy","article-title":"Topical administration of anticancer drugs for skin cancer treatment","author":"Taveira","year":"2011"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.002_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol Pract Concept"},{"issue":"7","key":"10.1016\/j.xphs.2019.06.002_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.mpmed.2017.04.003","article-title":"Skin cancer","volume":"45","author":"Craythorne","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.xphs.2019.06.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.03.013","article-title":"Melanoma circulating tumor cells: benefits and challenges required for clinical application","volume":"424","author":"Marsavela","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.xphs.2019.06.002_bib5","first-page":"364","article-title":"Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis","volume":"82","author":"Markovic","year":"2007"},{"issue":"9715","key":"10.1016\/j.xphs.2019.06.002_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)61196-X","article-title":"Non-melanoma skin cancer","volume":"375","author":"Madan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2019.06.002_bib7","series-title":"Melanoma","first-page":"209","article-title":"Chemotherapy for melanoma","author":"Wilson","year":"2016"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.002_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.xphs.2019.06.002_bib9","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.002_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.002_bib11","first-page":"219","article-title":"Use of nutraceuticals for prevention and treatment of cancer","volume":"12","author":"Salami","year":"2013","journal-title":"Iran J Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.002_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"Tse","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.002_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CMR.0b013e3282f60097","article-title":"Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells","volume":"18","author":"Saito","year":"2008","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1016\/j.xphs.2019.06.002_bib14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nrc1751","article-title":"Statins and cancer prevention","volume":"5","author":"Demierre","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.xphs.2019.06.002_bib15","first-page":"80","article-title":"The lipid organisation in the skin barrier","author":"Bouwstra","year":"2000","journal-title":"Acta Dermatovenereola"},{"issue":"20","key":"10.1016\/j.xphs.2019.06.002_bib16","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.2174\/1381612821666150428124053","article-title":"Overcoming the skin permeation barrier: challenges and opportunities","volume":"21","author":"Vitorino","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.xphs.2019.06.002_bib17","first-page":"2065","article-title":"Skin barrier and transdermal drug delivery","volume":"3","author":"Prausnitz","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.xphs.2019.06.002_bib18","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"M\u00fcller","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.002_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv Pharm Bull"},{"issue":"3 PART A","key":"10.1016\/j.xphs.2019.06.002_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","article-title":"Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review","volume":"85","author":"Hadinoto","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2019.06.002_bib21","series-title":"Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Nanocarriers","first-page":"161","article-title":"Nanostructured lipid carriers (NLC): the second generation of solid lipid nanoparticles BT","author":"M\u00fcller","year":"2016"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.06.002_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"M\u00fcller","year":"2002","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2019.06.002_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.addr.2007.04.006","article-title":"Lipid nanoparticles for improved topical application of drugs for skin diseases","volume":"59","author":"Sch\u00e4fer-Korting","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.xphs.2019.06.002_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/DSS.0000000000001115","article-title":"Long-term outcomes of melanoma in situ treated with topical 5% imiquimod cream: a retrospective review","volume":"43","author":"Park","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.xphs.2019.06.002_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2015.01.002","article-title":"Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin","volume":"91","author":"Frederiksen","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.002_bib26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1208\/s12249-009-9294-2","article-title":"Polymeric matrix system for prolonged delivery of tramadol hydrochloride, part II: biological evaluation","volume":"10","author":"Ammar","year":"2009","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.xphs.2019.06.002_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2013.02.011","article-title":"Co-encapsulating nanostructured lipid carriers for transdermal application: from experimental design to the molecular detail","volume":"167","author":"Vitorino","year":"2013","journal-title":"J\u00a0Control Release"},{"issue":"19","key":"10.1016\/j.xphs.2019.06.002_bib28","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1039\/c3ay40757h","article-title":"A\u00a0rapid reversed-phase HPLC method for the simultaneous analysis of olanzapine and simvastatin in dual nanostructured lipid carriers","volume":"5","author":"Vitorino","year":"2013","journal-title":"Anal Methods"},{"key":"10.1016\/j.xphs.2019.06.002_bib29","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acs.molpharmaceut.7b00211","article-title":"Expanding transdermal delivery with lipid nanoparticles\u202f: a new drug-in-NLC-in-adhesive design","volume":"14","author":"Mendes","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2019.06.002_bib30","first-page":"197","article-title":"Methods for studying percutaneous absorption","volume":"119","author":"Brain","year":"2002","journal-title":"Drugs Pharm Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.06.002_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jconrel.2005.04.007","article-title":"Ethosomes for skin delivery of ammonium glycyrrhizinate: in\u00a0vitro percutaneous permeation through human skin and in\u00a0vivo anti-inflammatory activity on human volunteers","volume":"106","author":"Paolino","year":"2005","journal-title":"J\u00a0Control Release"},{"issue":"4","key":"10.1016\/j.xphs.2019.06.002_bib32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10544-007-9046-6","article-title":"In\u00a0vitro and in\u00a0vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery","volume":"9","author":"Paolino","year":"2007","journal-title":"Biomed Microdevices"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.002_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000056341","article-title":"EEMCO guidance for the assessment of transepidermal water loss in cosmetic sciences","volume":"14","author":"Rogiers","year":"2001","journal-title":"Skin Pharmacol Physiol"},{"issue":"11","key":"10.1016\/j.xphs.2019.06.002_bib34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1600-0625.2006.00482.x","article-title":"Approaches for optimizing the calibration standard of Tewameter TM 300","volume":"15","author":"Miteva","year":"2006","journal-title":"Exp Dermatol"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.06.002_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2010.10.013","article-title":"Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system","volume":"403","author":"Luo","year":"2011","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.06.002_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2016.09.065","article-title":"Can lipid nanoparticles improve intestinal absorption?","volume":"515","author":"Mendes","year":"2016","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2019.06.002_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/10837450.2016.1200615","article-title":"How can lipid nanocarriers improve transdermal delivery of olanzapine?","volume":"22","author":"Iqbal","year":"2017","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"10.1016\/j.xphs.2019.06.002_bib38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.colsurfb.2010.07.029","article-title":"Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC","volume":"81","author":"Gonzalez-Mira","year":"2010","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"11","key":"10.1016\/j.xphs.2019.06.002_bib39","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.bbamem.2009.08.015","article-title":"Enhancement of transdermal drug delivery via synergistic action of chemicals","volume":"1788","author":"Karande","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.xphs.2019.06.002_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1517\/17425247.2012.637107","article-title":"Adhesive properties: a critical issue in transdermal patch development","volume":"9","author":"Cilurzo","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"1-2","key":"10.1016\/j.xphs.2019.06.002_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijpharm.2009.12.051","article-title":"In\u00a0vitro permeation and in\u00a0vivo whitening effect of topical hesperetin microemulsion delivery system","volume":"388","author":"Tsai","year":"2010","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2019.06.002_bib42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1600-0536.1992.tb00129.x","article-title":"Air oxidation of d-limonene (the citrus solvent) creates potent allergens","volume":"26","author":"Karlberg","year":"1992","journal-title":"Contact Dermatitis"},{"issue":"5","key":"10.1016\/j.xphs.2019.06.002_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1523-1747.ep12504896","article-title":"Sodium lauryl sulphate for irritant patch testing-a dose-response study using bioengineering methods for determination of skin irritation","volume":"95","author":"Agner","year":"1990","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.xphs.2019.06.002_bib44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/j.1552-4604.1990.tb01856.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin","volume":"30","author":"Pan","year":"1990","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.xphs.2019.06.002_bib45","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.addr.2009.09.005","article-title":"Squalene: a natural triterpene for use in disease management and therapy","volume":"61","author":"Reddy","year":"2009","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919303703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919303703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:26:29Z","timestamp":1758360389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354919303703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0022354919303703"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.06.002","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid Nanostructured Films for Topical Administration of Simvastatin as Coadjuvant Treatment of Melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}